Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041640857> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2041640857 endingPage "A467" @default.
- W2041640857 startingPage "A467" @default.
- W2041640857 abstract "To identify empirical threshold values for cost-effectiveness on the basis of past decisions in Agency for Health Technology Assessment (AHTAPol) in Poland and National Institute for Health and Clinical Excellence (NICE) in the UK for cancer drug technologies. Review of recommendations issued by AHTAPol and NICE for cancer drug technologies was performed. Period under investigation was August 2007 to March 2011 for AHTAPol and March 2000 – March 2011 for NICE. To identify empirical threshold values in both agencies, a comparison of ICER cost/QALY and past decisions was made. In the studied period AHTAPol and NICE issued, respectively, 44 and 54 recommendations for cancer drug technologies. Negative recommendations prevailed in Poland (43%). Most common recommendations in NICE were positive recommendations with major restriction (39%).The most commonly used measure of cost-effectiveness in NICE was ICER cost/QALY (41 recommendations) while in Poland it was identified only in 16 recommendations. As a result of a comparison of ICER cost/QALY and past decisions empirical threshold values in both agencies were not identified. In Poland four positive recommendations with restrictions and 9 negative ones were placed above official AHTAPol's threshold. In the same time, only 3 positive recommendations with or without restriction were below the threshold. In NICE, 17 positive recommendations with or without restrictions and 11 negative ones were above the official threshold value of £30,000/QALY. Below this threshold, there were 13 positive recommendations with or without restrictions. AHTAPol, as well as NICE, don't have definite empirical cost-effectiveness threshold values for cancer drug technologies. The official threshold values set in both agencies are not respected in the case of cancer drugs. Implementation of additional guidelines for “end-of-life” treatment in NICE may have potential impact on decisions concerning cost-effectiveness of cancer drug technologies." @default.
- W2041640857 created "2016-06-24" @default.
- W2041640857 creator A5027046932 @default.
- W2041640857 creator A5053261583 @default.
- W2041640857 creator A5089739343 @default.
- W2041640857 date "2011-11-01" @default.
- W2041640857 modified "2023-09-26" @default.
- W2041640857 title "PCN180 Threshold Values for Cost-Effectiveness in AHTAPol and NICE for Cancer Drug Technologies" @default.
- W2041640857 doi "https://doi.org/10.1016/j.jval.2011.08.1279" @default.
- W2041640857 hasPublicationYear "2011" @default.
- W2041640857 type Work @default.
- W2041640857 sameAs 2041640857 @default.
- W2041640857 citedByCount "0" @default.
- W2041640857 crossrefType "journal-article" @default.
- W2041640857 hasAuthorship W2041640857A5027046932 @default.
- W2041640857 hasAuthorship W2041640857A5053261583 @default.
- W2041640857 hasAuthorship W2041640857A5089739343 @default.
- W2041640857 hasBestOaLocation W20416408571 @default.
- W2041640857 hasConcept C112930515 @default.
- W2041640857 hasConcept C121608353 @default.
- W2041640857 hasConcept C126322002 @default.
- W2041640857 hasConcept C160735492 @default.
- W2041640857 hasConcept C162118730 @default.
- W2041640857 hasConcept C162324750 @default.
- W2041640857 hasConcept C17744445 @default.
- W2041640857 hasConcept C199360897 @default.
- W2041640857 hasConcept C199539241 @default.
- W2041640857 hasConcept C21333345 @default.
- W2041640857 hasConcept C2777352838 @default.
- W2041640857 hasConcept C2779256446 @default.
- W2041640857 hasConcept C3019080777 @default.
- W2041640857 hasConcept C3020340455 @default.
- W2041640857 hasConcept C41008148 @default.
- W2041640857 hasConcept C50522688 @default.
- W2041640857 hasConcept C71924100 @default.
- W2041640857 hasConceptScore W2041640857C112930515 @default.
- W2041640857 hasConceptScore W2041640857C121608353 @default.
- W2041640857 hasConceptScore W2041640857C126322002 @default.
- W2041640857 hasConceptScore W2041640857C160735492 @default.
- W2041640857 hasConceptScore W2041640857C162118730 @default.
- W2041640857 hasConceptScore W2041640857C162324750 @default.
- W2041640857 hasConceptScore W2041640857C17744445 @default.
- W2041640857 hasConceptScore W2041640857C199360897 @default.
- W2041640857 hasConceptScore W2041640857C199539241 @default.
- W2041640857 hasConceptScore W2041640857C21333345 @default.
- W2041640857 hasConceptScore W2041640857C2777352838 @default.
- W2041640857 hasConceptScore W2041640857C2779256446 @default.
- W2041640857 hasConceptScore W2041640857C3019080777 @default.
- W2041640857 hasConceptScore W2041640857C3020340455 @default.
- W2041640857 hasConceptScore W2041640857C41008148 @default.
- W2041640857 hasConceptScore W2041640857C50522688 @default.
- W2041640857 hasConceptScore W2041640857C71924100 @default.
- W2041640857 hasIssue "7" @default.
- W2041640857 hasLocation W20416408571 @default.
- W2041640857 hasOpenAccess W2041640857 @default.
- W2041640857 hasPrimaryLocation W20416408571 @default.
- W2041640857 hasRelatedWork W1860207377 @default.
- W2041640857 hasRelatedWork W2025373866 @default.
- W2041640857 hasRelatedWork W2461591074 @default.
- W2041640857 hasRelatedWork W2510133446 @default.
- W2041640857 hasRelatedWork W2544355323 @default.
- W2041640857 hasRelatedWork W2783959085 @default.
- W2041640857 hasRelatedWork W3088119602 @default.
- W2041640857 hasRelatedWork W4206658108 @default.
- W2041640857 hasRelatedWork W4250571798 @default.
- W2041640857 hasRelatedWork W48400510 @default.
- W2041640857 hasVolume "14" @default.
- W2041640857 isParatext "false" @default.
- W2041640857 isRetracted "false" @default.
- W2041640857 magId "2041640857" @default.
- W2041640857 workType "article" @default.